These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1254 related articles for article (PubMed ID: 16549511)
1. Antimicrobial activity of a novel peptide deformylase inhibitor, LBM415, tested against respiratory tract and cutaneous infection pathogens: a global surveillance report (2003-2004). Watters AA; Jones RN; Leeds JA; Denys G; Sader HS; Fritsche TR J Antimicrob Chemother; 2006 May; 57(5):914-23. PubMed ID: 16549511 [TBL] [Abstract][Full Text] [Related]
2. Antimicrobial activity of tigecycline tested against organisms causing community-acquired respiratory tract infection and nosocomial pneumonia. Fritsche TR; Sader HS; Stilwell MG; Dowzicky MJ; Jones RN Diagn Microbiol Infect Dis; 2005 Jul; 52(3):187-93. PubMed ID: 16105563 [TBL] [Abstract][Full Text] [Related]
3. Update of cefditoren activity tested against community-acquired pathogens associated with infections of the respiratory tract and skin and skin structures, including recent pharmacodynamic considerations. Biedenbach DJ; Jones RN Diagn Microbiol Infect Dis; 2009 Jun; 64(2):202-12. PubMed ID: 19321284 [TBL] [Abstract][Full Text] [Related]
4. Potency and spectrum of garenoxacin tested against an international collection of skin and soft tissue infection pathogens: report from the SENTRY antimicrobial surveillance program (1999-2004). Fritsche TR; Sader HS; Jones RN Diagn Microbiol Infect Dis; 2007 May; 58(1):19-26. PubMed ID: 17383139 [TBL] [Abstract][Full Text] [Related]
5. Antimicrobial activity of tigecycline tested against nosocomial bacterial pathogens from patients hospitalized in the intensive care unit. Sader HS; Jones RN; Dowzicky MJ; Fritsche TR Diagn Microbiol Infect Dis; 2005 Jul; 52(3):203-8. PubMed ID: 16105565 [TBL] [Abstract][Full Text] [Related]
6. Comparisons of parenteral broad-spectrum cephalosporins tested against bacterial isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (1998-2004). Jones RN; Sader HS; Fritsche TR; Pottumarthy S Diagn Microbiol Infect Dis; 2007 Jan; 57(1):109-16. PubMed ID: 16930923 [TBL] [Abstract][Full Text] [Related]
7. In vitro activity of tigecycline (GAR-936) tested against 11,859 recent clinical isolates associated with community-acquired respiratory tract and gram-positive cutaneous infections. Fritsche TR; Kirby JT; Jones RN Diagn Microbiol Infect Dis; 2004 Jul; 49(3):201-9. PubMed ID: 15246511 [TBL] [Abstract][Full Text] [Related]
8. Potency and spectrum of tigecycline tested against an international collection of bacterial pathogens associated with skin and soft tissue infections (2000-2004). Fritsche TR; Sader HS; Stilwell MG; Dowzicky MJ; Jones RN Diagn Microbiol Infect Dis; 2005 Jul; 52(3):195-201. PubMed ID: 16105564 [TBL] [Abstract][Full Text] [Related]
9. Activity of garenoxacin, an investigational des-F(6)-quinolone, tested against pathogens from community-acquired respiratory tract infections, including those with elevated or resistant-level fluoroquinolone MIC values. Jones RN; Fritsche TR; Sader HS; Stilwell MG Diagn Microbiol Infect Dis; 2007 May; 58(1):9-17. PubMed ID: 17408903 [TBL] [Abstract][Full Text] [Related]
10. The Alexander Project 1998-2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents. Jacobs MR; Felmingham D; Appelbaum PC; Grüneberg RN; J Antimicrob Chemother; 2003 Aug; 52(2):229-46. PubMed ID: 12865398 [TBL] [Abstract][Full Text] [Related]
11. Antimicrobial activity of doripenem tested against prevalent Gram-positive pathogens: results from a global surveillance study (2003-2007). Fritsche TR; Sader HS; Stillwell MG; Jones RN Diagn Microbiol Infect Dis; 2009 Apr; 63(4):440-6. PubMed ID: 19302928 [TBL] [Abstract][Full Text] [Related]
12. Antimicrobial susceptibility of bacterial pathogens associated with community-acquired respiratory tract infections in Asia: report from the Community-Acquired Respiratory Tract Infection Pathogen Surveillance (CARTIPS) study, 2009-2010. Wang H; Chen M; Xu Y; Sun H; Yang Q; Hu Y; Cao B; Chu Y; Liu Y; Zhang R; Yu Y; Sun Z; Zhuo C; Ni Y; Hu B; Tan TY; Hsueh PR; Wang JH; Ko WC; Chen YH; Wahjono H Int J Antimicrob Agents; 2011 Nov; 38(5):376-83. PubMed ID: 21880469 [TBL] [Abstract][Full Text] [Related]
13. Doripenem (S-4661), a novel carbapenem: comparative activity against contemporary pathogens including bactericidal action and preliminary in vitro methods evaluations. Jones RN; Huynh HK; Biedenbach DJ; Fritsche TR; Sader HS J Antimicrob Chemother; 2004 Jul; 54(1):144-54. PubMed ID: 15190031 [TBL] [Abstract][Full Text] [Related]
14. Antimicrobial activity of doripenem (S-4661): a global surveillance report (2003). Fritsche TR; Stilwell MG; Jones RN Clin Microbiol Infect; 2005 Dec; 11(12):974-84. PubMed ID: 16307551 [TBL] [Abstract][Full Text] [Related]
15. Zyvox Annual Appraisal of Potency and Spectrum program: linezolid surveillance program results for 2008. Jones RN; Ross JE; Bell JM; Utsuki U; Fumiaki I; Kobayashi I; Turnidge JD Diagn Microbiol Infect Dis; 2009 Dec; 65(4):404-13. PubMed ID: 19913683 [TBL] [Abstract][Full Text] [Related]
16. Prevalence of antimicrobial resistance among respiratory tract isolates in Latin America: results from SENTRY antimicrobial surveillance program (1997-98). Sader HS; Gales AC; Granacher TD; Pfaller MA; Jones RN; Braz J Infect Dis; 2000 Oct; 4(5):245-54. PubMed ID: 11063556 [TBL] [Abstract][Full Text] [Related]
17. Antimicrobial characterisation of CEM-101 activity against respiratory tract pathogens, including multidrug-resistant pneumococcal serogroup 19A isolates. Farrell DJ; Sader HS; Castanheira M; Biedenbach DJ; Rhomberg PR; Jones RN Int J Antimicrob Agents; 2010 Jun; 35(6):537-43. PubMed ID: 20211548 [TBL] [Abstract][Full Text] [Related]
18. Antimicrobial activity of ceftobiprole, a novel anti-methicillin-resistant Staphylococcus aureus cephalosporin, tested against contemporary pathogens: results from the SENTRY Antimicrobial Surveillance Program (2005-2006). Fritsche TR; Sader HS; Jones RN Diagn Microbiol Infect Dis; 2008 May; 61(1):86-95. PubMed ID: 18385000 [TBL] [Abstract][Full Text] [Related]
19. Antimicrobial activity of omiganan pentahydrochloride tested against contemporary bacterial pathogens commonly responsible for catheter-associated infections. Fritsche TR; Rhomberg PR; Sader HS; Jones RN J Antimicrob Chemother; 2008 May; 61(5):1092-8. PubMed ID: 18310135 [TBL] [Abstract][Full Text] [Related]
20. Potency and spectrum trends for cefepime tested against 65746 clinical bacterial isolates collected in North American medical centers: results from the SENTRY Antimicrobial Surveillance Program (1998-2003). Sader HS; Fritsche TR; Jones RN Diagn Microbiol Infect Dis; 2005 Jul; 52(3):265-73. PubMed ID: 16105569 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]